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Increased acid excretion may promote renal injury.
To evaluate this in African Americans with hypertensive
nephrosclerosis, we studied the association between the
net endogenous acid production and progression of kidney
disease in 632 patients in the AASK trial. Protein and
potassium intakes were estimated from 24h urea nitrogen
and potassium excretion, and used to estimate net
endogenous acid production, averaged over 2 years,
approximating routine intake. The link between net
endogenous acid production and the I125iothalamate
glomerular filtration rate (iGFR) and time to end-stage renal
disease or doubling of serum creatinine was analyzed using
mixed models and Cox proportional hazards regressions.
The trend in higher net endogenous acid production was
significantly associated with a faster decline in iGFR over a
median of 3.2 years. After adjustment for age, body mass
index, baseline iGFR, urine protein-to-creatinine ratio, and
randomized treatment group, the trend in higher net
endogenous acid production remained significantly
associated with a faster decline in iGFR at a rate of 1.01ml/
min per 1.73m2 per year faster in the highest compared
to the lowest quartile. However, in time-to-event analyses
over a median of 7.7 years, the adjusted hazard ratio (1.10)
for composite renal events per 25mEq/day higher net
endogenous acid production was not significant. Hence, our
findings implicate endogenous acid production as a potential
modifiable risk factor for progressive kidney disease.
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Chronic kidney disease (CKD) is a major public health
problem affecting 13% of the US population.1 Increased risks
of morbidity and mortality are evident even among those
with only mild decreases in kidney function.2 Preventive
strategies that are low cost, low risk, and scalable are needed
to address the epidemic of kidney disease.
Metabolic acidosis, a consequence of decreased renal acid
excretion, is a modifiable risk factor for CKD progression.3–5
In CKD, overall acid excretion is impaired with increased per
nephron acid excretion to compensate for nephron loss.6,7 In
turn, increased acid excretion by the nephron may promote
tubulointerstitial injury and contribute to disease progres-
sion.8,9 Alkali supplements can lower acid excretion and slow
disease progression.4,10 Manipulation of the net endogenous
acid production through diet may be an additional strategy
to decrease renal acid excretion that may be more amenable
to wide implementation as a public health initiative.
Net endogenous acid production is determined by the
balance of fixed acid and alkali precursors in the diet. Fixed
acid in the diet is derived largely from protein intake and
alkali from organic anions such as citrate and acetate, which
are naturally bound to cations, such as potassium.11 For this
reason, net endogenous acid production can be estimated
from the ratio of protein and potassium in the diet.12–14
In this study, we estimate net endogenous acid production in
this manner and evaluate its association with CKD progres-
sion in a cohort of African Americans with CKD.
RESULTS
A total of 632 participants from the African American
Study of Kidney Disease and Hypertension (AASK) trial
and cohort study were included in this analysis. The reasons
for exclusion are summarized in Figure 1. Median age was
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55 years (range 22–70 years). Median I125iothalamate glomer-
ular filtration rate (iGFR) was 48.6ml/min per 1.73m2
(interquartile range 36.6–58.5ml/min per 1.73m2). Median
estimated net endogenous acid production was 72.8mEq/day
(interquartile range 57.2–89.5mEq/day). Median estimated
protein intake was 64.9 g/day (interquartile range 53.1–76.3 g/day)
and median estimated potassium intake was 43.5mEq/day
(interquartile range 33.8–55.9 mEq/day). The baseline
characteristics of the study population stratified by quartiles
of net endogenous acid production are presented in Table 1.
Higher net endogenous acid production was associated with
current smoking, lower income, and lower serum bicarbo-
nate. Differences in protein intake across categories of NEAP
were smaller than differences in potassium intake.
The iGFR analysis
The slope of iGFR was estimated from all available iGFR
measurements performed every 6 months during the AASK
Table 1 | Baseline characteristics of the study population by quartiles of net endogenous acid production (NEAP)
Quartiles of NEAP (mEq/day)
1 (18.2–57.1) 2 (57.2–72.8) 3 (72.9–89.5) 4 (89.6–232.5)
Characteristic: mean±s.d. or n (%) (n=158) (n=158) (n=158) (n=158) P-valuea
Age (years) 55±10 56±10 54±11 54±11 0.41
Female sex (%) 63 (39.9) 56 (35.4) 69 (43.7) 51 (32.3) 0.17
History of heart disease (%) 84 (53.2) 75 (47.5) 79 (50.0) 87 (55.1) 0.54
Smoking (%) 0.01
Never 73 (46.2) 63 (39.9) 62 (39.2) 66 (41.8)
Former 55 (34.8) 55 (34.8) 43 (27.2) 35 (22.2)
Current 30 (19.0) 40 (25.3) 53 (33.5) 57 (36.1)
Total income (%)b 0.01
o$15,000 65 (41.1) 66 (41.8) 74 (46.8) 84 (53.2)
X$15,000 68 (43.0) 72 (45.6) 50 (31.7) 42 (26.6)
Body mass index (kg/m2) 30.3±6.4 30.3±6.2 29.3±5.5 29.5±6.4 0.10
Body mass index (%) 0.07
o25 kg/m2 25 (15.8) 34 (21.5) 36 (22.8) 45 (28.5)
25–30 kg/m2 67 (42.4) 52 (32.9) 61 (38.6) 45 (28.5)
430 kg/m2 66 (41.8) 72 (45.6) 61 (38.6) 68 (43.0)
Randomized to low BP goal (%) 80 (50.6) 86 (54.4) 72 (45.6) 69 (43.7) 0.21
Randomized drug (%) 0.58
Ramipril 57 (36.1) 68 (43.0) 64 (40.5) 61 (38.6)
Metoprolol 65 (41.1) 55 (34.8) 68 (43.0) 67 (42.4)
Amlodipine 36 (22.8) 35 (22.2) 26 (16.5) 30 (19.0)
Serum phosphorus (mg/dl) 3.5±0.6 3.5±0.6 3.6±0.7 3.5±0.6 0.55
Serum bicarbonate (mEq/l) 25.7±2.9 25.7±2.8 25.0±2.9 24.6±3.3 o0.001
Serum potassium (mEq/l) 4.1±0.5 4.1±0.6 4.1±0.5 4.2±0.5 0.07
Serum potassium 45.0mEq/l 7 (4.4) 6 (3.8) 9 (5.7) 7 (4.4) 0.88
Urine protein/creatinine (%)b 0.29
o0.22 104 (65.8) 118 (74.7) 108 (68.4) 116 (73.4)
0.22–0.99 37 (23.4) 27 (17.1) 27 (17.1) 29 (18.4)
X1.00 15 (9.4) 13 (9.4) 22 (13.9) 12 (7.6)
iGFR (ml/min per 1.73m2) 46.5±13.4 48.1±13.7 46.4±13.9 48.1±13.1 0.52
Estimated protein intake (g/day)c 64.6±19.1 64.6±16.4 66.3±16.6 68.4±20.4 0.04
Estimated potassium intake (mEq/day)c 65.4±20.3 47.8±12.8 40.5±10.2 32.4±10.7 o0.001
Abbreviations: BP, blood pressure; iGFR, I125iothalamate glomerular filtration rate.
aP-value is P-trend by univariate linear regression (continuous variables) or Pearson’s w2 (categorical variables).
bColumn % do not total 100 because of missing data.
cEstimated from 24 h urine collections between 12 and 36 months after randomization in the African American Study of Kidney Disease and Hypertension (AASK) trial phase.
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Figure 1 | Summary of reasons for participant exclusion from
study population.
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trial. A mean of 6.9 iGFR measurements were available per
individual to estimate iGFR slope over a median of 3.2 years.
The association of dietary intake and iGFR slope over
follow-up in the trial phase is presented in Table 2. In
unadjusted models, there was a faster rate of decline in iGFR
with higher quartiles of net endogenous acid production
(P-trend¼ 0.05), with an absolute difference in iGFR slope
of 0.86ml/min per 1.73m2 per year (95% confidence
interval 1.72 to 0.01; P¼ 0.05) in the highest compared
with the lowest quartile. After adjustment for age, body
mass index, randomized treatment group, baseline iGFR, and
urine protein-to-creatinine ratio (UPCR), higher quartiles
of net endogenous acid production remained associated
with a higher rate of decline (that is, more negative slope) in
iGFR over follow-up (P-trend¼ 0.01). Higher quartiles of
net endogenous acid production remained associated with a
higher rate of decline in iGFR (P-trend¼ 0.02) after further
adjustment for serum bicarbonate.
Estimated protein intake was not associated with iGFR
slope in unadjusted or adjusted models (P-trend¼ 0.13 and
0.37, respectively). Estimated potassium intake was not asso-
ciated with the rate of iGFR decline in unadjusted models
(P-trend¼ 0.51), but higher potassium intake was marginally
associated with a slower rate of iGFR decline after adjustment
(P-trend¼ 0.07). Adjusted differences in iGFR slope across
quartiles of dietary intake are summarized in Figure 2.
The association between net endogenous acid production
and iGFR slope was similar for participants with mild/
moderate CKD (iGFR445ml/min per 1.73m2) versus more
advanced CKD (iGFR p45ml/min per 1.73m2; P-inter-
action¼ 0.69; Table 3). There was some evidence that the
association between net endogenous acid production and
iGFR slope may differ for those with proteinuria, defined as
UPCR X0.22 versus not (UPCR o0.22). Among partici-
pants with UPCRo0.22, higher quartiles of net endogenous
acid production were associated with a higher rate of
decline in iGFR in a graded fashion (P-trend o0.01), but
not among participants with UPCR X0.22 (P-trend¼ 0.84).
The interaction between quartiles of net endogenous acid
production and UPCR was not statistically significant
Table 2 | I125iothalamate glomerular filtration rate (iGFR) slopes (ml/min per 1.73m2 per year) by quartiles of estimated net
endogenous acid production (NEAP), dietary protein intake, and dietary potassium intake
iGFR slope (ml/min per 1.73m2 per year)
Unadjusted Adjusteda Bicarbonate adjustedb
Quartiles
Absolute slope
(95% CI)
Difference from
Q1 (95% CI) P-value
Difference from
Q1 (95% CI) P-value
Difference from
Q1 (95% CI) P-value
Estimated NEAP
1 1.45 (2.02, 0.88) Ref — Ref — Ref —
2 2.11 (2.75, 1.46) 0.59 (1.44, 0.26) 0.17 0.69 (1.46, 0.09) 0.08 0.69 (1.45, 0.08) 0.08
3 2.25 (2.85, 1.65) 0.76 (1.61, 0.10) 0.08 0.85 (1.63, 0.08) 0.03 0.82 (1.59, 0.04) 0.04
4 2.34 (2.93, 1.76) 0.86 (1.72, 0.01) 0.05 1.01 (1.79, 0.23) 0.01 0.94 (1.72, 0.16) 0.02
P-trend 0.05 0.01 0.02
Estimated protein intake
1 1.99 (2.58, 1.39) Ref — Ref — Ref —
2 1.24 (1.82, 0.66) 0.66 (0.21, 1.54) 0.14 0.60 (0.23, 1.42) 0.16 0.54 (0.28, 1.36) 0.20
3 2.58 (3.17, 1.98) 0.57 (1.43, 0.29) 0.19 0.42 (1.25, 0.42) 0.33 0.45 (1.28, 0.38) 0.29
4 2.26 (2.88, 1.64) 0.28 (1.13, 0.57) 0.52 0.05 (0.90, 0.80) 0.91 0.04 (0.89, 0.80) 0.92
P-trend 0.13 0.37 0.39
Estimated potassium intake
1 2.26 (2.85, 1.66) Ref — Ref — Ref —
2 2.00 (2.53, 1.47) 0.15 (0.73, 1.02) 0.74 0.27 (0.55, 1.08) 0.52 0.26 (0.55, 1.07) 0.53
3 1.88 (2.51, 1.25) 0.38 (0.50, 1.26) 0.40 0.63 (0.20, 1.45) 0.14 0.57 (0.25, 1.39) 0.17
4 2.05 (2.70, 1.40) 0.24 (0.63, 1.11) 0.59 0.71 (0.13, 1.54) 0.10 0.65 (0.18, 1.49) 0.13
P-trend 0.51 0.07 0.09
Abbreviations: CI, confidence interval; Q1, quartile 1.
aSlopes adjusted for randomized blood pressure and drug groups and categories of age, proteinuria, baseline GFR, and body mass index.
bAdjusted for above plus quartiles of serum bicarbonate.
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Figure 2 |Adjusted difference in I125iothalamate glomerular
filtration rate (iGFR) slope (ml/min per 1.73m2 per year) by
quartiles of net endogenous acid production (NEAP), and
protein and potassium intake. The iGFR slopes are estimated
using mixed effect models adjusted for randomized blood
pressure and drug groups and categories of age, proteinuria,
baseline GFR, and body mass index.
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(P-interaction¼ 0.19). Finally, the association between quar-
tiles of net endogenous acid production and iGFR slope was
present among a more restricted subgroup of participants
with serum bicarbonate above current clinical practice targets
(X22mEq/l; n¼ 564). In this subgroup, participants in the
highest quartile of net endogenous acid production had an
absolute difference in iGFR slope of 0.97ml/min per
1.73m2 per year (95% confidence interval 1.86 to 0.09;
P¼ 0.03) compared with the lowest quartile, with a trend
across quartiles (P-trend¼ 0.03).
Time-to-renal-event analysis
There were 229 renal events (end-stage renal disease (ESRD)
or doubling of serum creatinine from trial baseline) over
long-term follow-up from 12 months after randomization
through the trial and cohort phases. A total of 70 participants
died before reaching the composite renal end point. Among
those with UPCR o0.22, there were 101 renal events
compared with 128 renal events among those with UPCR
X0.22. The adjusted association between quartiles of net
endogenous acid production and composite renal events is
presented overall and stratified by categories of UPCR in
Table 4. There was no statistically significant association
between higher net endogenous acid production and
composite renal events overall (P¼ 0.17). Among those with
UPCR o0.22, higher net endogenous acid production was
associated with composite renal events (P¼ 0.05), although
the interaction was not statistically significant (P¼ 0.32).
Sensitivity analyses
Analyses using estimates of net endogenous acid production
obtained from all urine collections, without exclusion
based on the total creatinine production, and using estimates
obtained from urine collections averaged between trial base-
line and 24 months after randomization, were unchanged
from the primary analyses. Additionally, in time-to-event
analyses, results were similar if death was included as a
component of the composite end point in lieu of being
treated as a competing risk.
DISCUSSION
In this study of African Americans with hypertensive
CKD, a dietary pattern resulting in higher net endogenous
acid production was associated with a faster rate of CKD
Table 3 | Adjusteda difference in I125iothalamate glomerular filtration rate (iGFR) slope (ml/min per 1.73m2 per year) compared
with lowest quartile associated with quartiles of estimated net endogenous acid production (NEAP) stratified by urine protein-
to-creatinine ratio (UPCR) and severity of kidney disease
Difference in iGFR slope (ml/min per 1.73m2 per year)
UPCR Baseline iGFR
o0.22
(n=444)
X0.22
(n=182)
p45ml/min per
1.73m2 (n=257)
445ml/min per
1.73m2 (n=369)
Quartiles
Difference from
Q1 (95% CI) P-value
Difference from
Q1 (95% CI) P-value
Difference from
Q1 (95% CI) P-value
Difference from
Q1 (95% CI) P-value
1 Ref — Ref — Ref — Ref —
2 0.73 (1.63, 0.18) 0.12 0.09 (1.46, 1.64) 0.91 0.54 (1.71, 0.63) 0.36 0.67 (1.69, 0.35) 0.20
3 0.88 (1.78, 0.03) 0.06 0.30 (1.78, 1.17) 0.69 0.77 (1.92, 0.39) 0.19 0.83 (1.86, 0.21) 0.12
4 1.29 (2.18, 0.40) o0.01 0.01 (1.64, 1.62) 0.99 1.68 (2.89, 0.47) o0.01 0.69 (1.70, 0.31) 0.18
P-trend o0.01 0.84 o0.01 0.18
P-interaction 0.19 0.69
Abbreviations: CI, confidence interval; Q1, quartile 1.
aSlopes adjusted for randomized blood pressure and drug groups and categories of age and body mass index. Models stratified by baseline iGFR are also adjusted for
categories of proteinuria and models stratified by UPCR are also adjusted for categories of baseline glomerular filtration rate.
Adjusted slope models include 626/632 participants (499%) because of missing covariate information in 6 participants.
Table 4 | Adjusteda hazard ratios for composite end-stage renal disease (ESRD) or doubling of serum creatinineb associated
with quartiles of net endogenous acid production (NEAP) and stratified by urine protein-to-creatinine ratio (UPCR)
Adjusted HR
Overall (n=625) UPCR o0.22 (n=444) UPCR X0.22 (n=181)
Quartiles of NEAP HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
1 1.0 — 1.0 — 1.0 —
2 0.95 (0.64, 1.41) 0.81 1.02 (0.58, 1.79) 0.95 0.77 (0.43, 1.37) 0.37
3 1.06 (0.73, 1.55) 0.76 1.06 (0.61, 1.87) 0.83 1.04 (0.62, 1.73) 0.89
4 1.22 (0.82, 1.83) 0.33 1.38 (0.77, 2.48) 0.28 1.26 (0.72, 2.18) 0.42
Continuous (per 25mEq/day) 1.10 (0.96, 1.26) 0.17 1.22 (1.00, 1.49) 0.05 1.07 (0.90, 1.27) 0.46
Abbreviations: CI, confidence interval; HR, hazard ratio.
aAdjusted for age, sex, baseline glomerular filtration rate (GFR), proteinuria, body mass index, income, randomized blood pressure and drug assignment, and study phase.
bDeath is treated as a competing risk.
Adjusted survival models include 625/632 participants (99%) because of missing covariate information in 7 participants.
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progression. To date, several observational and randomized
studies have implicated low serum bicarbonate levels as a
modifiable risk factor for CKD progression.3–5 Lowering net
endogenous acid production of the diet may raise serum
bicarbonate13 and may be an alternative strategy to target
abnormal acid base homeostasis in CKD without large
sodium loads.
The association between net endogenous acid production
and CKD progression was independent of serum bicarbonate
and similar in a subset achieving target serum bicarbonate
levels,15 suggesting that the risk associated with net endo-
genous acid production may not be due to its effect on serum
bicarbonate per se. We acknowledge that serum bicarbonate
concentration can be prone to measurement error and
it is possible that we were not able to fully account for the
effect of serum bicarbonate in these models.3 However,
several additional studies support mechanisms of renal injury
due to acidic diets that are independent of serum bicarbonate
concentration. Animal studies have shown that diets gene-
rating high net endogenous acid production may accelerate
renal injury by increasing demand for renal ammonium
excretion,8 and by promoting intracellular acidosis, both of
which develop before clinically overt metabolic acidosis.16,17
Other human studies have demonstrated that modulation
of net endogenous acid production through administration
of fixed acid or alkali alters the rate of GFR decline and
profibrotic mediators in the urine such as endothelin and
aldosterone without clinically relevant changes in serum
bicarbonate.10,18
In our analyses, we did not observe strong evidence that
the association between net endogenous acid production
and CKD progression varies by baseline CKD stage. In both
the slope and time-to-event analyses, we did observe that the
association between net endogenous acid production and
CKD progression was stronger among those without protein-
uria. We would interpret these findings cautiously given that
the statistical test of interaction was not significant, and
statistical significance within one subgroup could be related,
in part, to a larger sample size. It is important to recognize,
however, that these analyses were highly stratified and had
limited power to test these interactions. Animal studies
suggest that renal acid loading specifically promotes tubu-
lointerstitial injury, a pattern characterized by less proteinur-
ia.8,19 Although the nonproteinuric group is at lower risk of
ESRD, they remain at elevated risk for mortality associated in
a graded fashion with decreased GFR.20
Point estimates of the association between net endogenous
acid production and time to ESRD or doubling of serum
creatinine were consistent with the findings from slope
analyses, but did not confirm these findings statistically. Our
power in these models was limited and the confidence
intervals did not exclude clinically important associations.
Additionally, less than half of the events occurred in the large
subpopulation of participants without proteinuria, the group
in whom net endogenous acid production appeared to be
a stronger risk factor in slope analyses.
In this population, the net endogenous acid production
was more strongly influenced by variability in potassium,
rather than protein, intake. It is important to note that the
net endogenous acid production considers the balance of
protein and potassium intake in the diet and was more
strongly associated with GFR decline than either protein or
potassium intake alone. Current clinical guidelines recom-
mend restricted protein intake in CKD.21 Although our study
does not refute these guidelines, it suggests that the balance of
protein intake with natural sources of alkali, such as fruits
and vegetables, may be more important. We were not able
to definitively evaluate the safety of such diets in patients
with CKD in this study, although the observed prevalence of
hyperkalemia was low.
This study has several limitations. The AASK study popu-
lation was highly selected, including only African Americans
with hypertensive kidney disease. For this reason, it is
difficult to generalize these results to other racial groups with
different dietary patterns or those with etiologies of kidney
disease other than hypertension. We do not have direct
measures of diet in this study. We are unable to account for
dietary factors other than total protein and potassium intake
that may affect endogenous acid production, including the
differential impact of protein from plant versus animal
sources and intake of additives in processed foods.
This study also has several important strengths. We have
multiple measures of the net endogenous acid production
through frequent 24 h urine collections, frequent measures
of iGFR over long-term follow-up, and careful collection
of patient characteristics, including detailed medication
histories. Additionally, we also have event data over a long
follow-up period across both the AASK trial and cohort
phases, allowing consideration of both GFR slope and time-
to-event analyses.
In conclusion, we have observed that higher net endo-
genous acid production is associated with a faster rate of
decline in GFR among African Americans with hypertensive
kidney disease. This association may be stronger among
patients without proteinuria. These results should be inter-
preted cautiously in light of results from time-to-event
models that are consistent with, but do not confirm statis-
tically, the findings seen in models of GFR slope. Our
findings implicate net endogenous acid production as a
potentially modifiable risk factor for progressive kidney
disease worthy of further study.
MATERIALS AND METHODS
Study population
The AASK trial was a multicenter, 2 3 factorial, randomized,
controlled trial of intensive vs. standard blood pressure control,
using one of three primary antihypertensive agents (ramipril,
metoprolol, or amlodipine), in self-identified African Americans
with hypertensive nephrosclerosis.22 Participants without ESRD at
the end of the trial were offered enrollment in an observational
cohort phase.23,24 This analysis includes 632 participants from AASK
with eligible urine collections between 12 and 36 months
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in the trial. Urine collections were eligible if the 24 h total creatinine
excretion was within 30% of the expected (22.1mg/kg in men
and 17.2mg/kg in women), indicating a complete collection,25 and
excluded if the participant was taking potassium or alkali supplements.
The protocol and procedures were approved by the institutional
review board of each center and all participants provided written
informed consent.
Data collection
The 24h urine collections were performed every 6 months throughout
the trial and annually in the cohort. Urine samples were analyzed at
a central laboratory for urea nitrogen, potassium, sodium and
creatinine. Ideal body weight (IBW) was calculated using previously
published equations.26 Dietary protein intake was estimated from
24 h urine urea nitrogen (UUN) excretion using the Maroni
equation (protein intake¼ 6.25 (UUNþ 0.031 IBW)–urinary
protein (g/day) if daily urine protein excretion X5 g).27 Dietary
potassium intake was estimated as the total 24 h urine potassium
excretion.28 Net endogenous acid production was estimated from
these intakes as previously described: net endogenous acid pro-
duction (mEq/day)¼10.2þ 54.5 (protein intake (g/day)C potassium
intake (mEq/day)).12 Estimates derived from urine samples collected
between 12 and 36 months after randomization were averaged to
provide a measure of habitual dietary intake. Urine samples from
the initial 12 months were not used because of frequent medication
titrations during this time that may have altered steady-state potas-
sium excretion. In all, 310 participants (49%) had 3 to 6 measure-
ments available, 137 participants (22%) had 2 measurements, and
185 participants (29%) had 1 measurement. Intake was also estimated
from eligible urine samples in the cohort phase and averaged over
the first 24 months for use in time-dependent Cox models.
I125iothalamate GFR was collected twice at baseline, and
at 3, 6, and every 6 months thereafter during the AASK trial phase.
Serum creatinine was used to estimate glomerular filtration rate
using a study-specific equation in the cohort phase.23,29 UPCR was
evaluated in spot urine samples at trial and cohort baseline. Renal
events occurring over combined follow-up in the trial and cohort
phases were defined as ESRD (initiation of dialysis or renal
transplantation) or doubling of serum creatinine from trial baseline.
Statistical analysis
Baseline characteristics of the study population were examined
across quartiles of net endogenous acid production using linear
regression (continuous variables) or Pearson’s w2 (categorical variables).
Values from trial baseline were used for these analyses, except for
serum phosphorus and bicarbonate, for which values from 12 months
after randomization were used. UPCR and iGFR from trial baseline
were selected given differential effects of the randomized drugs on
proteinuria and acute effects on iGFR.
The association between net endogenous acid production and
the rate of change of iGFR from 12 months after randomization to
the end of the trial was evaluated using linear mixed models with
maximum likelihood estimation (median follow-up 3.2 years).
Covariates hypothesized to contribute to CKD progression were
included in adjusted models if they were associated with iGFR slope
in univariate analyses (Po0.10) or significantly improved adjusted
model fit. Models were adjusted for age (in quartiles), randomized group,
body mass index (categorized aso25, 25–30, and430kg/m2), baseline
iGFR (categorized as460, 46–60, 31–45, andp30ml/min per 1.73m2)
and proteinuria (categorized as baseline UPCR o0.22, 0.22–0.99 or
X1.00). A subsequential adjustment was then made for serum
bicarbonate (categorized in quartiles). Secondary analyses evaluated
the association of estimated protein and potassium intake with iGFR
slope.
The association between net endogenous acid production and the
relative risk of composite renal events from 12 months after
randomization through follow-up in the cohort (median of 7.7
years) was tested using time-dependent Cox proportional hazards
models with death treated as a competing risk.30 Net endogenous acid
production was analyzed as time-varying with updated exposure
classification at cohort baseline. Models were adjusted for age, sex,
categories of income, baseline GFR (time-varying: baseline iGFR for
trial phase; baseline estimated GFR for cohort phase), log UPCR
(time-varying), categories of body mass index (time-varying), study
phase (trial vs. cohort), and randomized blood pressure and
antihypertensive drug assignment. Secondary analyses evaluated the
association of estimated protein and potassium intake with renal
events. Sensitivity analyses evaluated a composite end point of death
and renal events.
Models were stratified by categories of baseline GFR (that is, iGFR
445 vs. p45ml/min per 1.73m2), proteinuria (UPCR o0.22 vs.
X0.22), and serum bicarbonate (o22 or X22mEq/l). The cut-point
for proteinuria was prespecified and has been used as a standard
threshold for all AASK analyses.31,32 Cut-points for GFR and serum
bicarbonate are clinically relevant cut-points, consistent with prior
literature and current practice guidelines.15 Interactions were tested
between net endogenous acid production and both baseline GFR and
proteinuria using interaction terms in adjusted models. Sensitivity
analyses were performed using estimates of net endogenous acid
production obtained from all urine samples without exclusion based
on the total creatinine, and using urine samples collections from trial
baseline to 24 months after randomization instead of 12 to 36 months.
All analyses were performed using STATA Special Edition 11.0
(College Station, TX, 2009). Hypotheses were tested using a two-sided
type 1 error rate of 0.05.
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